New Drug Combo Boosts Survival Against Aggressive Form of Breast Cancer

Published on September 20, 2021

New research offers good news for women with an aggressive HER2-positive breast cancer. A targeted therapy, trastuzumab deruxtecan (T-DXd), sold as Enhertu, triples the length of time that the cancer remains in check when compared with the current gold standard, trastuzumab…

Read Full Article (External Site)